Government Funded research Archives - Page 18 of 44

10 March 2021: South Africa raises the banner for the TRIPS waiver at the WTO

Posted on March 11, 2021 by Thiru

On 10 March 2021, the World Trade Organization’s (WTO) TRIPS Council addressed the proposal for a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 (IP/C/W/669) under agenda item 12. This proposal is… Continue Reading →

KEI Response to Questions from USTR on Special 301 – March 5, 2021

Posted on March 8, 2021 by KEI Staff

On Friday, March 5, 2021, Knowledge Ecology International (KEI) submitted written responses to questions from USTR on Special 301. The pdf version of KEI’s written submission can be found here.

NIST Proposed Revisions to Bayh-Dole Act Regulations

Posted on February 26, 2021 by Claire Cassedy

New: Biden White House Executive Order opposes change in Bayh-Dole March-In regulations. (KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a… Continue Reading →

KEI RN-2021-1. US government COVID contracts definitions of practical application

KEI Research Note 2021-1. February 2021. US government COVID contracts definitions of practical application. Link

KEI Comments to NIH Proposed Exclusive License to Ziopharm for Cell Therapy Cancer Treatment

Posted on February 12, 2021 by Claire Cassedy

On February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” to Ziopharm Oncology, Inc. (Ziopharm). The… Continue Reading →

KEI Comments on NIH Exclusive License to Canadian Firm EpifiZa

Posted on February 12, 2021 by Claire Cassedy

On Tuesday February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment… Continue Reading →

Exclusive License to NIH Invention Used in Lilly Antibody Treatment Contains Termination Clause and Government-Use Rights

Posted on February 2, 2021 by Kathryn Ardizzone

KEI has reviewed an exclusive license between the National Institute of Allergy and Infectious Diseases (NIAID) and AbCellera Biologics (“AbCellera”) concerning a technology invented by NIAID that apparently is being used for the Eli Lilly (“Lilly”) antibody treatment for COVID-19… Continue Reading →

Draft of EU export restriction for COVID-19 vaccines

Posted on January 29, 2021 by KEI Staff

This is the draft regulation: EU export ban, tradoc_159398

Novavax and Inovio COVID-19 Vaccine Contracts Limit Prices Companies Can Charge for Their Products

Posted on January 28, 2021 by Kathryn Ardizzone

One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading →

Agenda: Jan 27, 2021 Discussion of proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes

Posted on January 26, 2021 by Staff

This is the agenda for a discussion of proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes. The proposals for the changes in regulations were noticed on January 4, 2021, and the proposed changes in the statutes were published on… Continue Reading →

Categories